Source
6 developments in the corpus
Latest
Everything in the corpus, newest first.
OCT 16, 2026 · JOURNAL ARTICLE
Biomarker Research
Post-translational modifications (PTMs) of histone H3 at lysine 9 (H3K9) contribute to chromatin homeostasis and transcriptional regulation and have been implicated in cancer progr
OCT 16, 2026 · JOURNAL ARTICLE
Biomarker Research
Attenuated oncolytic bacteria represent a promising targeted delivery platform for cancer therapy; however, the lack of non-invasive biomarkers to monitor their persistent intra-tu
OCT 9, 2026 · JOURNAL ARTICLE
Biomarker Research
N⁴-acetylcytidine (ac⁴C) is an evolutionarily conserved RNA modification that was initially identified in transfer RNA (tRNA) and ribosomal RNA (rRNA). Increasing evidence has subs
OCT 9, 2026 · JOURNAL ARTICLE
Biomarker Research
CD133 (prominin-1) is among the most widely used cancer stem cell markers, yet two decades of research have yielded persistent contradictions: CD133-negative cells can be tumorigen
SEP 9, 2026 · JOURNAL ARTICLE
Biomarker Research
A narrative review synthesizing preclinical mechanistic evidence on VHL targets and proposing therapeutic modalities, lacking clinical trial data or human evidence to support practice recommendations.
AUG 10, 2026 · JOURNAL ARTICLE
Biomarker Research
Preclinical mechanistic study in transgenic mice and PDX models with a novel protein delivery approach; no clinical efficacy data or human trials reported, only mechanism validation and proof-of-concept in xenografts.